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A B S T R A C T
The worldwide prevalence of diabetes has reached 8.5% among adults, and this is characterised by elevated
glucose concentrations and failing insulin secretion. Furthermore, most people with type 2 diabetes are either
obese or overweight, with the associated dyslipidaemia contributing to the development of insulin resistance
and increased cardiovascular risk. Here we incubated INS-1 pancreatic β-cells for 72h in RPMI-1640 media,
or media supplemented with 28mM glucose, 200µM palmitic acid, and 200µM oleic acid as a cellular model
of diabetic glucolipotoxicity. Illumina HiSeq gene expression analysis showed the trace amine-associated recep-
tor (TAAR) family to be among the most highly downregulated by glucolipotoxicity. Importantly, MetaCore in-
tegrated knowledge database, from Clarivate Analytics, indicated potential TAAR impact on insulin secretion
through adenylyl cyclase signalling pathways. We therefore investigated the effect of TAAR ligands on cAMP
signalling and insulin secretion, and found that only the branch of the TAAR family tree that is activated by
isopentylamine, 2-phenylethylamine, p-tyramine, and agmatine significantly increased intracellular cAMP and re-
sulted in increased insulin secretion from INS-1 cells and primary mouse islets under normal conditions. Crucially
however, this enhancement was not evident when the receptor family was downregulated by glucolipotoxic con-
ditions. This data indicates that a subset of TAARs are regulators of insulin secretion in pancreatic β-cells, and
that their downregulation contributes to glucolipotoxic inhibition of insulin secretion. As such they may be po-
tential targets for treatment of type 2 diabetes.
1. Introduction
Over 80% of patients with type 2 diabetes (T2D) are either over-
weight or obese, and typically this is associated with insulin resistance.
Consequently, these patients have both elevated blood glucose and free
fatty acid concentrations [1]. It is known that chronic hyperglycaemia
inhibits stimulated insulin secretion, but it is the combination of both
high sugar and high fat that has the largest detrimental effect on β-cell
function [2]. We previously employed microarray technology to in-
vestigate the effect of glucolipotoxicity upon INS-1 pancreatic β-cell
gene expression, and found a wide spectrum of damaging effects in-
cluding diminished insulin secretion, chronic inflammation, increased
apoptosis, biological oxidation, and dysregulated nucleic acid process-
ing and repair [3]. Furthermore, based on ranked statistical signifi-
cance of enrichment following MetaCore integrated knowledge database
analysis (https://clarivate.com/products/metacore) of that dataset, we
also demonstrated the presence of disease association with both en-
docrine and metabolic disorders, which indicates the presence of path-
ways in INS-1 cells with known T2D and obesity aetiology in man [3].
Although microarray technology has proven successful, the develop-
ment of next generation sequencing (RNAseq) technology offers a num-
ber of advantages over microarray approaches. For example, microar-
ray analysis is limited by the need to rely upon existing knowledge of
genome sequence, they have high background levels due to cross-hy-
bridization, and a limited dynamic range of detection due to both back-
ground and saturation of signals. By contrast, next generation sequenc-
ing strategies analyse total amount of reads that map to the exons of a
gene, normalised by the length of the exons, and do not have an up-
per limit for quantification [4]. The presence and amount of each RNA
can therefore be calculated and subsequently compared with the amount
in any other sequenced sample. In addition, RNAseq data also have
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high levels of reproducibility for both technical (repeated measurements
of the same sample) and biological (parallel measurements of biologi-
cally distinct samples) replicates.
Building from our previous work [2,3], we utilised Illumina HiSeq
gene expression analysis to more accurately define the pathophysiology
of type 2 diabetes, with a view to identifying potential new targets for
therapeutic intervention. Data presented here indicate that downregula-
tion of trace amine-associated receptor signalling contributes to the fail-
ure of insulin secretion that results from chronic exposure of pancreatic
β-cells to high concentrations of glucose and fatty acids. Furthermore,
under control conditions, only stimulation of family members associated
with one specific arm of the TAAR phylogenic tree enhanced insulin se-
cretion. We propose that future studies focus on this specific subset of
family members as potential new therapeutic targets for treatment of
type 2 diabetes.
2. Materials and methods
2.1. Materials
Antibodies were obtained from Abcam (Cambridge, UK) and Agilent
Technologies (Santa Clara, CA, USA). Unless otherwise stated, all other
chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) or
VWR International Ltd (Lutterworth, UK).
2.2. Islet isolation and INS-1 β-cell culture
Islets were isolated from male CD1 mice by collagenase injection into
the pancreatic duct. Digested pancreas was washed with MEM-2279 and
separated from exocrine tissues by centrifuging through a Histopaque
1.077 g/ml gradient. After washing, islets were picked and incubated at
37 °C in RPMI-1640 (supplemented with 10% [vol/vol] fetal calf serum,
2mM glutamine and 100U/ml penicillin/ 0.1mg/ml streptomycin) for
24h prior to further analysis. INS-1 rat pancreatic β-cells were cultured
in RPMI-1640 media, or RPMI media supplemented with 28mM glu-
cose, 200µM oleic acid, and 200µM palmitic acid (GLT media), for 72h
as detailed previously [2]. All animal procedures were approved by the
King’s College London Ethics Committee and carried out in accordance
with the UK Home Office Animals (Scientific Procedures) Act 1986.
2.3. Cell viability
INS-1 cells were cultured in either RPMI 1640 or GLT media for
72h. Media was aspirated and cells washed three times in modified
Krebs-Ringer solution (KRB) (125mM NaCl, 1.2mM KH2PO4, 5mM KCl,
2mM MgSO4, 1mM CaCl2, 1.67mM glucose, 0.1% BSA, 25mM HEPES,
pH7.4). Cells were then incubated in KRB media supplemented with a fi-
nal concentration of 5µM Calcein AM Cell Viability Dye (ThermoFisher)
for 1h, before being washed in KRB for a final time. Cell viability was
measured via fluorescence, with excitation and emission at 490nm and
520nm respectively.
2.4. RNA isolation
Cells were incubated in the appropriate conditions for 72h, har-
vested and RNA extracted using an RNA isolation kit (Life Technolo-
gies, UK). RNA integrity was assessed using a 2100 Bioanalyzer (Agi-
lent Technologies Inc., Santa Clara, CA), with all samples analysed in
this study having a RIN score >8. Samples for transcriptome analy-
sis were prepared using a Truseq™ RNA Sample Prep Kit (Illumina
Inc., San Diego, CA, USA) according to the manufacturer’s recommen-
dations. Briefly, mRNA was isolated from>5µg of total RNA using
oligo (dT) magnetic beads. mRNA was cut into short fragments by
adding fragmentation buffer. First-strand cDNA was synthesized using
random hexamer-primers, taking these short fragments as templates.
RNaseH, buffer, dNTPs, and DNA polymerase I was used to synthesize
second-strand cDNA. Short fragments were purified with Takara’s PCR
extraction kit (Takara Bio, Inc.). Sequencing adapters were ligated to
short fragments and resolved by agarose gel electrophoresis. Fragments
were then selected, purified, and subsequently PCR amplified to create
the final cDNA library template.
2.5. Next generation sequencing
Library was generated from the fragmentation of mRNA in small
pieces using divalent cations under elevated temperature, with the frag-
ments converted to first strand cDNA using reverse transcriptase and
random primers. Subsequently the RNA template was removed and a re-
placement cDNA strand synthesized, generating a double strand-cDNA.
The fragments were then end-repaired, in a process that converts the
overhangs into blunt ends, using T4 DNA polymerase and Klenow DNA
polymerase. Adapters were then ligated to the DNA fragments, prepar-
ing them to be hybridized to a single read flow cell. cDNA samples were
purified on a gel to select a size range of templates (around 200bp) for
downstream enrichment. The purified cDNA templates were enriched
using PCR to amplify the cDNA in the library, using primers that anneal
to the ends of the adapters. The library was validated by performing
a quality control analysis to quantify DNA concentration using Agilent
Bioanalyzer. Library was then used to perform paired end sequencing
over one lane of a flow cell on an Illumina HiSeq™ 2000 instrument at
a read depth of ~65 million reads per sample.
2.6. Expression analysis
In the sequencing process, the Illumina instrument produced qual-
ity-scored base calls. The sequencing output files (compressed FASTQ
files) were then used for the secondary analysis.
Reads were aligned to an annotated reference genome using Top Hat
v 2.0.9: http://tophat.cbcb.umd.edu. Reads aligned to exons, genes and
splice junctions are counted using the reference genome “rn4”, extracted
from UCSC (http://genome.ucsc.edu/goldenPath/credits.html#rat_
credits). Data visualisation and interpretation, calculating gene as well
as transcript expression, then reporting differential expression, was done
using the HTseq-count program:
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.html).
Normalization, which corrects for in-sample distributional differences
within the read counts was performed using the program DEseq:
(http://www.bioconductor.org/packages/devel/bioc/html/DESeq.
html).
Statistical significance of fold changes was calculated by comparing
the experimental read values to the control samples, with p values ad-
justed using the Bonferroni formula.
2.7. Pathway identification and visualization
For comprehensive analysis of biological pathways in which tran-
scripts were differentially expressed we combined expression data from
the next generation sequencing analysis with information in Reactome
version 29, (http://www.reactome.org), a knowledgebase of biological
pathways [5]. In order to visualize the networks we used MetaCore ver-
sion 6.34, build 69200 from Clarivate Analytics (http://genego.com), an
integrated knowledge-based platform for pathway analysis. Data analy-
sis tools were used to generate high-resolution images of networks, with
details of network objects and interactions provided in the Metacore leg-
end.
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2.8. Quantitative RT-PCR
INS-1 cells were trypsinised, washed with cold phosphate-buffered
saline (PBS) (13.7mM NaCl, 0.27mM KCl, 1mM Na2HPO4, 0.2mM
KH2PO4, and pH7.4) and lysed in RNAeasy QTL lysis buffer. Total RNA
was prepared from lysed cells using RNeasy kit (Qiagen, Hilden, Ger-
many) according to manufacturers recommended procedures (Qiagen).
cDNA was generated from RNA using a standard RT kit (Promega, Madi-
son, WI, USA). qRT-PCR reactions were performed using Maxima SYBR
Green/ROX qPCR Master Mix (ThermoFisher Scientific, Loughborough,
UK) and the following primers: TAAR1 forward GAAGGAGTTGAG-
GAGCAGTATC; TAAR1 reverse AAGACGTCATGAATGCCAGTA; TAAR2
forward AATGACTATTCCGGTCGTCAAG; TAAR2 reverse
CCATCAGCATAAGCCTCTGAA; TAAR3 forward GGTATGCAGAGCTAC-
GAGATTC; TAAR3 reverse CATGATGGAGCCAGGAGTAAA; TAAR4 for-
ward CATGATCGGAGCGATAGTGATG; TAAR4 reverse GTGGTAGC-
CATGGAGAGAATAAG; TAAR5 forward CTC-
CAAGTTCACAGTCAGGATAG; TAAR5 reverse GTAGAGAAAGAAG-
GCAGTGTAGG; TAAR6 forward CAGGAATTTGCATCAGCATCTC;
TAAR6 reverse CTCCAGGCCATCAGCATAAA; TAAR7b forward TCT-
GCTCTCAGCCTCATCTA; TAAR7b reverse CCAAAGCCAAAGACTG-
CATAAA; TAAR9 forward CCAAGTTCACCATTTCGGTTTC; TAAR9 re-
verse CTCGTTGGCTCCTGTGTAAA; GAPDH forward CATCTCCCTCA-
CAATTCCATCC; GAPDH reverse GAGGGTGCAGCGAACTTTAT. Due to
the high homology between TAAR7 and TAAR8 only one primer pair
(TAAR7) was designed to amplify these family members [6]. Target
gene mRNA was quantified and normalised for GAPDH using an
ABI7700 bioanalyzer (Applied Biosystems, Foster City, CA, USA). Data
were analysed using the ΔΔCTmethod.
2.9. Western blotting
INS-1 cells were lysed, protein separated by SDS-PAGE, then trans-
ferred to nitrocellulose as described previously [2]. Protein was de-
tected using anti-TAAR1 (Abcam, Cambridge, UK) primary antibody and
polyclonal goat anti-rabbit horseradish peroxidase conjugated secondary
antibody (Agilent Technologies, Santa Clara, CA, USA).
2.10. cAMP determination
INS-1 cells were treated with TAAR ligands (either isopentylamine,
p-tyramine, 2-phenylethylamine, agmatine, N,N-dimethylcyclohexy-
lamine, N,N-dimethyloctylamine, or the inverse agonist EPPTB) sus-
pended in KRB plus 0.5mM IBMX for half an hour prior to cAMP de-
termination. Cells were then lysed in 0.1M HCl according to manufac-
turer’s protocol, and cAMP accumulation level determined using cAMP
Select ELISA kit (Cayman Chemical Company, Ann Arbour, MI, USA).
2.11. Insulin secretion
INS-1 cells were treated with KRB or KRB supplemented with sec-
retagogue cocktail (13.5mM glucose, 1µM phorbol 12-myristate 13-ac-
etate, 1mM isobutyl-methylxanthine, 1mM tolbutamide, 10mM
leucine, 10mM glutamine) for 2h prior to determination. Supernatant
was removed and insulin secretion was determined using an ELISA kit
as detailed previously [2]. Size-matched islets were pre-incubated for
1h at 37 °C in buffer containing 2mM glucose, 2mM CaCl2 and 0.5mg/
ml BSA, pH 7.4. Islets were further incubated in buffer containing 2 or
20mM glucose for 1h±stated amine concentration at 37 °C with gentle
shaking. Insulin secretion was measured by radioimmunoassay with an
in-house 125I-labelled insulin tracer as previously detailed [7].
2.12. Statistical analysis
Results are expressed as mean±standard error of the mean (n=3
or more independent experiments). Parameters were compared using
one-tailed student t-test assuming equal variance, with statistical signifi-
cance determined using an alpha value of 5%. A p value below 0.05 was
therefore considered to be statistically significant.
3. Results
3.1. Impact of glucolipotoxicity upon β-cell protein classes
In order to better understand the mechanisms by which chronic ex-
posure to high glucose and fatty acids alters cellular function, we incu-
bated INS-1 rat pancreatic β-cells for 72h in RPMI-1640 media, or me-
dia supplemented with 28mM glucose, 200μM oleic acid, and 200μM
palmitic acid (GLT media), conditions previously characterised for the
study of the effects of glucolipotoxicity upon insulin secretion (2). Total
RNA was isolated and sequencing undertaken using an Illumina HiSeq™
2000 instrument (Illumina Inc., San Diego, CA, USA). Genes differen-
tially expressed in conditions of high glucose/high fat relative to control
(with p<0.05) were analysed using PANTHER gene ontology software
(http://www.pantherdb.org) in order to determine those that have the
greatest differential expression associated with glucolipotoxicity. The
program calculates the number of genes that are enriched within a spe-
cific pathway, and the associated statistical significance of enrichment.
Enrichment is considered statistically significant when there are more
genes in the list associated with a particular pathway than would be ex-
pected by chance based on the total number of genes associated with
that pathway. As can be seen (Table 1), G-protein-coupled receptor
(GPCR) signalling was found to be the most significant of any specific
protein class differentially expressed. We therefore focussed the remain-
der of the current study on GPCR families that are differentially ex-
pressed within our RNAseq dataset, and which might therefore con-
tribute to β-cell dysfunction caused by glucolipotoxicity.
3.2. Trace amine-associated receptor family downregulation by
glucolipotoxicity
Of note, among the GPCR families differentially regulated by high
glucose and fatty acids, the trace amine-associated receptor (TAAR) fam-
ily stands out as all members are downregulated following 72h incu-
bation in GLT media. Indeed, TAAR3, 4, 5, 6, 7a, 7b, 7c, 7d, 7e, 7g,
7h, 8b, 8c and 9 are downregulated to the level of detection sensitiv-
ity (Fig. 1a). As we had incubated cells under control, high glucose,
Table 1
Differential expression of protein family classes.
Protein class p Value
Receptor 1.88 E−38
G-protein coupled receptor 1.67 E−24
RNA binding protein 3.54 E−20
Ribosomal protein 1.54 E−18
Signalling molecule 1.28 E−17
Nucleic acid binding 2.91 E−17
Transporter 8.91 E−16
Immunoglobulin 1.13 E−13
Ion Channel 2.72 E−13
Cell adhesion molecule 4.58 E−11
Comparative analysis of gene expression from INS-1 cells incubated for 72h in RPMI-1640
media supplemented with or without 28mM glucose, plus 200μM oleic acid, and 200μM
palmitic acid. Data is compiled from six independent RNAseq analyses (three per experi-
mental group).
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Fig. 1. Effect of glucolipotoxicity on TAAR family expression. a) INS-1 cells were cultured in RPMI-1640 media, or media supplemented with 28mM glucose, 200µM oleic acid and 200µM
palmitic acid, or 28mM glucose plus 200µM oleic acid and 200µM palmitic acid (GLT) for 72h. RNA was extracted and Illumina HiSeq analysis undertaken. Data is expressed as RNA read
counts per condition. b) INS-1 cells were cultured in RPMI-1640, or GLT media for 72h. RNA was extracted and qRT-PCR undertaken using the primers and cycle conditions detailed in
the Methods section. c) INS-1 cells were grown in RPMI-1640, or GLT media for 72h. Protein was extracted and separated by SDS-PAGE, transferred to nitrocellulose, and detected using
anti-TAAR1 primary antibody. In all cases data are expressed as mean±SEM from 3 or more independent experiments. *p<0.05 **p<0.005 ***p<0.0005.
high fatty acid, and high glucose plus high fatty acid conditions we were
also able to determine the extent to which glucose and fatty acids drive
down regulation both individually and together. Glucose and fatty acids
each drive down expression significantly (p<0.05 in all cases, except
for TAAR1 in high fatty acid). Importantly however, combination treat-
ment with high glucose and high fat (GLT media) had the largest down-
regulation on all TAAR members.
In order to validate these results, we next performed independent
qRT-PCR analysis of the TAAR family members TAAR1, 2, 3, 4, 5, 6,
7b and 9 (Fig. 1b) from cells incubated +/− GLT media for 72h. In
all cases TAAR expression was significantly downregulated by GLT me-
dia, with values ranging from 30.2%±12.0% (p=0.033) for TAAR4,
to 60.8%±10.2% (p=0.002) for TAAR7b. RNA does not always cor-
respond to protein expression however, so it is also important to quan-
tify protein expression between control and GLT conditions. Therefore,
INS-1 β-cells were again cultured +/− GLT media for 72h, cells lysed,
and immunoblotted using antibody against TAAR1 (Fig. 1c), the only
TAAR family member for which a commercial antibody was available
(Abcam, Cambridge, UK). Densitometry analysis indicated that TAAR1
protein expression was downregulated by 42.6%±9.1% in comparison
to GLT media (p=0.0017). Furthermore, these data are not the result of
altered β-cell viability resulting from exposure to glucolipotoxic media,
as INS-1 cells incubated for 72h in GLT media had 103.7±3.4% cell vi-
ability relative to RPMI-1640 media control (data not shown).
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3.3. Impact of glucolipotoxicity upon the TAAR1 interactome
In order to better understand how TAAR family downregulation
might impact upon pancreatic β-cell function, non-biased network
analysis was performed using the MetaCore integrated knowledge data-
base of pathways (https://portal.genego.com). Expression data from
the RNAseq analysis files was used as the input list for generation of
biological networks using the Analyze network algorithm with default
settings. By so doing we were able to generate a bespoke network of
molecules predicted to interact with the most extensively characterised
member of the TAAR family, TAAR1 (Fig. 2). Those genes upregulated
by GLT in our experiments are indicated by an adjacent red circle in
the interactome, whereas those genes that are downregulated are in-
dicated by a blue circle. Our data indicate that when TAAR1 (shown
as TAR1 in Fig. 2) is downregulated by glucolipotoxicity there are
Fig. 2. Network analysis of TAAR1 signalling. INS-1 cells were cultured in RPMI-1640 media, or media supplemented with 28mM glucose, 200µM oleic acid and 200µM palmitic acid,
(GLT) for 72h. RNA was extracted and Illumina HiSeq analysis undertaken. MetaCore software (http://genego.com) was utilised to construct an interactome linked to TAAR1 (TAR1).
Significantly upregulated genes (Bonferroni corrected p value<0.05) are indicated by an adjacent red circle, whereas downregulated genes are indicated by an adjacent blue circle.
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both positive and negative downstream effects on GPCR signalling
through Gα pathways. Specifically, stimulatory Gαs protein is downregu-
lated, whereas inhibitory Gαi protein is upregulated. The consequence of
these complementary effects would be a concerted negative downstream
action upon adenylyl cyclase. Furthermore, such an effect would reduce
ATP conversion to cAMP, a molecule known to amplify insulin secretion
from pancreatic β-cells [8].
3.4. Effect of TAAR ligands upon cAMP level and insulin secretion
The TAAR1 interactome is consistent with previous literature that
has indicated an association between TAAR1 signalling and adeny-
lyl cyclases via Gαs proteins [9]. We therefore sought to determine
whether physiological TAAR ligands could enhance insulin secretion
via cAMP pathways in β-cells. INS-1 cells were grown in RPMI-1640
media, then washed and incubated in KRB and 0.5mM IBMX, or KRB
and 0.5mM IBMX supplemented with the trace amine ligands, isopenty-
lamine (TAAR3), p-tyramine (TAAR1 and TAAR4), 2-phenylethylamine
(TAAR1 and TAAR4), agmatine (putative TAAR6 and TAAR8 ligand),
N,N-dimethylcyclohexylamine (TAAR7, TAAR8 and TAAR9 isoforms),
and N,N-dimethyloctylamine (TAAR7 isoforms) at a single final con-
centration of 10µM for direct comparison, or the TAAR1 inverse ago-
nist EPPTB at a concentration of 10nM, for 30min. Cells were lysed
in 0.1M HCl and cAMP determined via select ELISA. Isopentylamine
was found to significantly increase the level of cAMP by 3.5±0.6 fold
(p=0.02) relative to control, whilst p-tyramine increased cAMP accu-
mulation by 3.8±0.5 fold (p=0.01), 2-phenylethylamine by 4.1±0.7
fold (p=0.02) and agmatine by 2.8±0.3 fold (p=0.005) respectively.
By contrast, incubation with EPPTB decreased the cAMP level to
0.78±0.04 (p=0.004), whilst N,N-dimethylcyclohexylamine and
N,N-dimethyloctylamine also resulted in a modest
decrease in cAMP level to 0.90±0.01 (p=0.003) and 0.83±0.05
(p=0.01) respectively (Fig. 3a).
In order to determine how this might relate to insulin secretion,
INS-1 cells were cultured to 70% confluency, washed, and then in-
cubated with either KRB or KRB secretagogue cocktail (supplemented
with 13.5mM glucose, 1µM phorbol 12-myristate 13-acetate, 1mM
isobutyl-methylxanthine, 1mM tolbutamide, 10mM leucine, 10mM glu-
tamine) along once more with, where indicated, isopentylamine, p-tyra-
mine, 2-phenylethylamine, agmatine, N,N-dimethylcyclohexylamine, or
N,N-dimethyloctylamine at a final concentration of 10µM, or the in-
verse agonist EPPTB at a concentration of 10nM, for 2h. Insulin secre-
tion was determined by ELISA (Mercodia, Uppsala, Sweden) and nor-
malised to cellular protein content. Data is presented as fold change rela-
tive to stimulated control from the corresponding experiment (Fig. 3b).
Consistent with our cAMP data, N,N-dimethylcyclohexylamine had no
significant effect upon secretagogue-stimulated insulin secretion, whilst
N,N-dimethyloctylamine and the TAAR1 inverse agonist, EPPTB, de-
creased secretion by 13.2%±5.0% (p=0.029) and 18.2%±4.0%
(p=0.005) respectively. By contrast, isopentylamine, p-tyramine, and
2-phenylethylamine significantly increased secretagogue-stimulated in-
sulin secretion by 16.8%±5.1% (p=0.0149), 23.3%±8.7%,
(p=0.045), and 26.5%±7.1% (p=0.0155) respectively. Agmatine
also caused a modest increase in stimulated insulin secretion by
16.0%±6.9%, albeit this was just outside statistical significance
(p=0.056). There was, however, no significant change in unstimulated
insulin secretion for all treated ligands compared to control.
In order to determine whether those ligands that enhance cAMP
and insulin secretion under standard conditions might make suitable
drug candidates for the treatment of T2D, we then repeated the insulin
secretion experiments in glucolipotoxic conditions. Our results show
that in the absence of ligands, GLT media decreased insulin secretion
Fig. 3. Effect of trace amines on cAMP and insulin secretion. a) INS-1 cells were grown in standard growth media before being washed and incubated in KRB and 0.5mM IBMX or KRB
and 0.5mM IBMX supplemented with either isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), agmatine (Agm), N,N-dimethylcyclohexylamine (Cyclo), or N,N-dimethy-
loctylamine (Ctyl) at a final concentration of 10µM, or the inverse agonist EPPTB at a concentration of 10nM, for 30min. Cells were lysed in 0.1M HCl and cAMP determined via select
ELISA. b) INS-1 cells were cultured in standard growth media to 70% confluency, washed, then incubated in either KRB [(−) blue] or KRB secretagogue cocktail [(+) red] (containing
13.5mM glucose, 1µM phorbol 12-myristate 13-acetate, 1mM isobutyl-methylxanthine, 1mM tolbutamide, 10mM leucine, 10mM glutamine), minus or plus trace amine ligands as indi-
cated: isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), agmatine (Agm), N,N-dimethylcyclohexylamine (Cyclo), N,N-dimethyloctylamine (Ctyl) at a final concentration
of 10µM, or TAAR1 inverse agonist EPPTB at a concentration of 10nM for 2h. Insulin secretion was then determined by ELISA (Mercodia, Sweden), and normalised to cellular protein
content. c) INS-1 cells were cultured in RPMI-1640 media, or RPMI-1640 GLT media for 72h. Insulin secretion was determined by ELISA assay following incubation±secretagogue cock-
tail [(−) blue, (+) red], minus or plus trace amine ligands as indicated: isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), or agmatine (Agm) at a final concentration of
10µM for 2h, with data normalized to cellular protein content. d) TAAR family phylogenetic tree, with trace amine ligand responsiveness mapped alongside. In all cases data are expressed
as mean±SEM from a minimum of 3 independent experiments. *p<0.05 **p<0.005 compared to control. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article).
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to 26.7±9.6% of control stimulated secretion values (Fig. 3c). Cru-
cially, however, all of the previously observed increases in insulin secre-
tion that had been seen under standard media conditions were no longer
observed when cells had been incubated in GLT media, where a decrease
in TAAR expression is seen.
Given the clear split in cellular response to the different amine lig-
ands under standard conditions, between those that enhance cAMP sig-
nalling and insulin secretion and those that do not, we then sought to
determine whether this might be explained by evolutionary divergence
within the TAAR family. The resulting phylogenetic tree, complete with
ligand responsiveness mapped alongside this, is shown in Fig. 3d.
The above data is fully consistent with a role for TAAR family mem-
bers 1–4 in insulin secretion. However, transformed β-cell lines are not
always fully representative of primary β-cell biology, and so it is impor-
tant to determine whether these findings are indicative of whole animal
physiology. In order to address this point pancreatic islets were isolated
from CD1 mice, then incubated with the monoamine oxidase inhibitor
pargyline (in order to prolong the half-life of administered tyramine)
and the indicated concentration of p-tyramine, and insulin secretion
determined (Fig. 4). p-Tyramine increased glucose-stimulated insulin
secretion by 33.2%±20.3% (p=0.199), 83.2%±11.8% (p=0.004),
41.2%±23.4% (p=0.156) and 47.8%±26.8% (p=0.067) at concen-
trations of 0.1µM, 1µM, 10µM and 100µM respectively. This U-shaped
curve and decrease in tyramine effect likely represents a loss of selectiv-
ity seen at concentrations of tyramine greater than 10μM, where there
are known to be competing mechanisms from interaction with other
pharmacological targets.
4. Discussion
Through Illumina HiSeq analysis of RNA that was extracted from
β-cells exposed to conditions of diabetic glucolipotoxicity, we have
been able to identify those genes that become dysregulated following
chronic exposure to high glucose and fatty acid levels. When analysed
for differential expression, receptor signalling showed the highest sta-
tistical significance. This indicates that the molecules involved in glu-
colipotoxicity are likely primarily implicated in signalling pathways,
in regulating transcription factors binding, and in molecular transport.
The former is consistent with our previous microarray experiments,
where we identified a novel role for TNFR5 signalling in initiating
NF-κB and STAT1 transcription factor activation and subsequent islet
Fig. 4. Dose-dependent effect of p-tyramine upon insulin secretion from mouse islets. Islets
were isolated from CD1 mice, then cultured in RPM1-1640 media for 24h. Islets were
then incubated in 2mM [(−) blue] or 20mM [(+) red] glucose for 1h, supplemented with
10µM paragyline±p-tyramine at the stated concentration, and insulin secretion deter-
mined by radioimmunoassay. Dara are expressed as mean±SEM from a minimum of 5
independent experiments. **p<0.005 compared to control stimulated (+) samples. (For
interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article).
inflammation that leads to β-cell apoptosis (3). However, our current
data shows that GPCR signalling was the most significant of any specific
protein class differentially expressed. Within this category, the TAAR
family were all substantially downregulated, many to the level of our
assay detection sensitivity, following 72h culture in GLT media. This
makes the TAAR family prime candidates for participation in insulin
stimulus-secretion coupling, which is significantly decreased by glucol-
ipotoxicity.
TAARs were first identified in 2001 as receptors for endogenous
trace amine ligands including p-tyramine, 2-phenylethylamine and
tryptamine [9,10]. Humans possess six functional TAARs, mice have fif-
teen, and rat seventeen. All, except TAAR1, have previously been shown
to also function as olfactory receptors [11–13]. In the case of TAAR1
the receptor signals via Gαs proteins to increase intracellular cAMP con-
centration [9,14,15]. In the olfactory epithelium however, all TAARs
appear to couple to Golf, though this also associates with adenylyl cy-
clase to increase cAMP [11,16,17]. TAARs have also been implicated in
neuropsychiatric disorders, where they modulate monoaminergic neuro-
transmission [18,19].
Importantly, TAAR1 has previously been shown to be expressed
in pancreatic β-cells from both human islets and mouse MIN-6 cells
[18,20,21]. Indeed, the discovery of the TAAR family was in part
due to screening of pancreatic tumour cell lines [9]. Administration
of the potent, although non-selective, TAAR1 ligand 3-iodothyronamine
strongly enhanced insulin secretion from MIN-6 cells [20]. More recent
studies with highly selective agonists have confirmed a TAAR1-mediated
enhancement of glucose-stimulated insulin secretion, an effect observed
in both INS-1 cells and isolated human islets [21]. Importantly TAAR1
agonists maintain efficacy in vivo, where improved glucose tolerance
has been observed, along with increased insulin secretion in response
to a glucose challenge [21]. Furthermore, single nucleotide polymor-
phisms of TAAR1 that result in altered signal transduction were recently
reported in a sub-set of patients exhibiting impaired insulin secretion
[22]. These studies therefore suggest that TAAR1 may be a novel ther-
apeutic target to treat type 2 diabetes. Crucially however, other TAAR
isoforms have not previously been studied in this context.
In order to further explore their potential as possible drug develop-
ment targets, we investigated the effect of endogenous ligands of the
wider TAAR family upon insulin secretion from INS-1 β-cells and pri-
mary mouse islets, with cells either incubated under standard condi-
tions or following 72h incubation in GLT media. Pharmacological stud-
ies of human, mouse and rat TAARs have shown that p-tyramine and
2-phenylethylamine activate TAAR1 and TAAR4 [10,19,23]. Isopenty-
lamine is a reported endogenous agonist for TAAR3 (11), while agma-
tine is only currently described as an agonist for TAAR 13c that has
currently only been found to be expressed in zebra fish [24]. The di-
amine binding site through which agmatine interacts with TAAR13c is,
however, conserved in both human and rodent TAAR6 and TAAR8 iso-
forms [24,25] making them potential sites through which agmatine ef-
fects might be mediated. The N,N-dimethylalkylamines, meanwhile, are
agonists at TAAR7 and TAAR9 isoforms [16]. Our data show that un-
der control conditions it is not only TAAR1 stimulation that has the
ability to influence glucose metabolism, but in fact ligands that acti-
vate TAAR1, TAAR3, and TAAR4. By contrast EPPTB, an inverse ago-
nist for TAAR1, and trace amine ligands that bind to TAAR7 and 9 had
no positive effect upon secretagogue-stimulated insulin secretion. The
positive effect of ligand activation in control conditions is also consis-
tent with our cAMP data, where higher insulin secretion was reflected
by higher intracellular cAMP concentrations. This was further validated
by the modest, albeit statistically non-significant, increase in insulin se-
cretion following agmatine stimulation, which similarly reflected the
smaller effect on cAMP increase. In addition, the inverse agonist EPPTB
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decreased cAMP levels and insulin secretion, further supporting the link
between cAMP level and secretion data.
TAARs 1–4 form one of the two major branches of the TAAR phy-
logenetic tree known as primary amine detectors. This suggests a con-
served genetic ancestry possibly involving the functional ability to reg-
ulate cAMP conversion from ATP through primary amine binding [26].
As shown (Fig. 3d), it is only ligands for these particular TAARs that
significantly enhance insulin secretion, whilst those that have no posi-
tive effect upon insulin secretion act on a separate branch of the phylo-
genetic tree. Agmatine would appear to be one possible exception to this
rule as it has only been previously described as an agonist for TAAR13c,
a receptor that has a binding site conserved with TAAR6 and TAAR8. Ze-
brafish TAAR13c is however nevertheless present on the same branch of
the phylogenetic tree as those receptors capable of regulating insulin se-
cretion [27], and while agmatine is known not to interact with TAAR1
[28] it is conceivable that agmatine may activate other TAARs of this
conserved mammalian branch of the tree that are currently incompletely
characterized. However, this is an area that requires further system-
atic study, particularly in light of agmatine's known poly-pharmacology.
As such the effects we observed in response to agmatine cannot be de-
finitively ascribed to one or more TAAR-family members at this time.
The above studies are consistent with TAAR representing a novel
therapeutic target for the treatment of type 2 diabetes. Furthermore,
previous work has shown TAAR1 agonists also have beneficial effects
on nutrient-induced hormone secretion from the gastrointestinal tract,
regulating glucagon-like peptide 1 (GLP-1) and peptide YY secretion
from intestinal L-cells [21], and somatostatin secretion from the stom-
ach D-cells [29]. Such potential benefit could be negated, however, by
our observation that glucolipotoxicity decreases the expression of the
receptors through which such effects are mediated. Indeed, our data
shows that the ability of these ligands to enhance insulin secretion was
lost when INS-1 cells were cultured in GLT media for 72h. This is in
agreement with our expression data, as downregulation of receptor ex-
pression following exposure to GLT media would reduce the potential
for receptor ligand binding and the resultant signal transduction which
leads to downstream increases in secretion. It is worth noting, how-
ever, that in other cell types a positive feedback loop has been sug-
gested whereby TAAR1 agonists induce increased expression of TAAR1.
As such, the non-selective TAAR1 agonist methamphetamine increases
TAAR1 expression in T leukocytes [30], with a similar effect also re-
cently reported in placenta in response to the highly selective TAAR1
agonist RO5203648 [31]. Should such an effect also occur in pancre-
atic β-cells following a longer-term administration than the 2h treat-
ment used here, this may allow for TAAR agonists to still be effective
and overcome the glucolipotoxicity-induced decrease in receptor expres-
sion. This is an area for future systematic study. In addition, studies
on the status of TAAR gene expression in human diabetic patients are
also needed, although as noted earlier signal-modifying TAAR1 poly-
morphisms have recently been linked to impaired insulin secretion in
certain patients [22].
Given that failure of insulin secretion leads to the onset of overt
diabetes, this has been a primary target for therapeutic intervention
since sulfonylurea compounds were first introduced as oral antidiabetic
agents in the 1950s. Indeed, these compounds remain an important
pharmacotherapy for the control of glucose homeostasis in patients with
T2D to this date. However, safety concerns over sulphonylureas have
started to arise in recent years, not least as their use can result in hy-
poglycemia and weight gain. In addition, over time they also often be-
come less effective. This has therefore resulted in a search for new com-
pounds, and especially those that are able to enhance insulin secre-
tion through different mechanisms. Unlike sulphonylureas, TAAR1 ag-
onists do not appear to promote hypoglycaemia [21]. They do how-
ever promote weight loss in models of excessive weight gain [18,21],
and moreover may even normalize binge eating phenotypes [32], of-
fering potential additional benefits over current frontline pharmacother-
apies. Importantly, TAAR1 has been confirmed in clinical trials as a
viable, safe, target to which pharmacotherapies can be targeted [33],
and as such TAAR1directed agents may be beneficial prophylactically in
pre-diabetic patients.
Sulphoylureas bind to and close pancreatic β-cell KATP channels,
resulting in cell membrane depolarisation and subsequent Lc-type
Ca2+-channel opening, Ca2+ influx, and exocytosis of insulin-containing
secretory granules [34]. More recently incretin mimetics have also been
employed to enhance insulin secretion. Their mechanism of action is dif-
ferent to sulphonylureas as, like TAARs, incretin receptors instead acti-
vate stimulatory cell membrane GPCRs linked to adenylyl cyclase. This
then generates cAMP, which in turn serves to amplify glucose-stimulated
insulin secretion [35,36]. Dipeptidyl peptidase 4 (DPP4) inhibitors, or
gliptins, also enhance incretin levels, albeit through inhibition of the en-
zymatic breakdown of incretins [37]. Consequently, they also therefore
enhance stimulatory GPCR signalling.
Whilst incretin mimetics are increasingly being advocated as a safer
alternative to enhance insulin secretion than sulphonylureas, these too
are not without problems. Firstly, hyperglycaemia has been shown to
significantly reduce expression of β-cell incretin receptors [38], not un-
like our current data showing downregulation of TAARs following ex-
posure to glucolipotoxicity. In addition, these drugs need to be adminis-
tered through subcutaneous injection, which is often unpopular with pa-
tients. In addition, some patients develop irritation at injection sites, fur-
ther adding to their unpopularity. However, DPP4 inhibitors and TAAR
agonists can be administered orally, thereby offering a less problematic
way to activate adenylyl cyclase. Therefore, in conclusion, whilst glu-
colipotoxic downregulation of TAAR family members 1–4 leads to a sig-
nificant reduction in insulin secretion, and therefore likely contributes
to T2D pathophysiology, use of new and existing therapies to augment
adenylyl cyclase activity through receptors linked to heterotrimeric Gαs
signalling pathways might prove effective at offsetting this deficiency.
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